CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Finch Therapeutics Group, Inc. - FNCH CFD

2.3938
6.3%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.0924
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.001
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Finch Therapeutics Group Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.2238
Open* 2.3338
1-Year Change* 490.39%
Day's Range* 2.3338 - 2.4138
52 wk Range 2.91-18.30
Average Volume (10 days) 17.08K
Average Volume (3 months) 503.57K
Market Cap 4.83M
P/E Ratio -100.00K
Shares Outstanding 1.61M
Revenue 115.00K
EPS -61.60
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 23, 2024 2.3938 0.0600 2.57% 2.3338 2.4138 2.3338
Feb 22, 2024 2.2238 0.0000 0.00% 2.2238 2.4038 2.2238
Feb 21, 2024 2.4738 0.0700 2.91% 2.4038 2.4738 2.3638
Feb 20, 2024 2.3938 -0.0800 -3.23% 2.4738 2.5438 2.3838
Feb 16, 2024 2.4138 0.1400 6.16% 2.2738 2.5238 2.2738
Feb 15, 2024 2.4438 0.1200 5.16% 2.3238 2.4438 2.2838
Feb 14, 2024 2.3138 0.0400 1.76% 2.2738 2.3238 2.2738
Feb 13, 2024 2.3938 0.0000 0.00% 2.3938 2.3938 2.3938
Feb 12, 2024 2.4638 0.0000 0.00% 2.4638 2.4638 2.4638
Feb 9, 2024 2.4438 -0.0600 -2.40% 2.5038 2.5538 2.4338
Feb 8, 2024 2.5438 0.1000 4.09% 2.4438 2.5438 2.3838
Feb 7, 2024 2.5038 -0.1100 -4.21% 2.6138 2.6438 2.5038
Feb 6, 2024 2.4638 -0.1000 -3.90% 2.5638 2.7838 2.3838
Feb 5, 2024 2.5338 0.0100 0.40% 2.5238 2.5938 2.5038
Feb 2, 2024 2.5838 -0.0800 -3.00% 2.6638 2.6838 2.4938
Feb 1, 2024 2.6838 0.0700 2.68% 2.6138 2.6838 2.6138
Jan 31, 2024 2.8338 0.0000 0.00% 2.8338 2.8438 2.8338
Jan 30, 2024 2.8438 0.0600 2.16% 2.7838 2.8438 2.7838
Jan 29, 2024 2.8838 0.0000 0.00% 2.8838 2.8938 2.8638
Jan 26, 2024 2.8738 0.0700 2.50% 2.8038 2.8838 2.8038

Finch Therapeutics Group, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 0.861 18.532 7.719 10.154
Revenue 0.861 18.532 7.719 10.154
Cost of Revenue, Total 0 0.314
Gross Profit 7.719 9.84
Total Operating Expense 116.454 76.69 47.155 31.296
Selling/General/Admin. Expenses, Total 38.088 21.238 14.011 7.439
Research & Development 57.893 57.279 33.144 23.543
Operating Income -115.593 -58.158 -39.436 -21.142
Interest Income (Expense), Net Non-Operating 0.252 0.022 0.106 0.488
Gain (Loss) on Sale of Assets -0.007 0.028 -0.013 -0.14
Other, Net 0.702 -0.052 0.002 0.04
Net Income Before Taxes -114.646 -58.16 -39.341 -20.754
Net Income After Taxes -114.646 -58.16 -39.341 -20.754
Net Income Before Extra. Items -114.646 -58.16 -39.341 -20.754
Net Income -114.646 -58.16 -39.341 -20.754
Income Available to Common Excl. Extra. Items -114.646 -58.16 -39.341 -20.754
Income Available to Common Incl. Extra. Items -114.646 -58.16 -39.341 -20.754
Diluted Net Income -114.646 -58.16 -39.341 -20.754
Diluted Weighted Average Shares 1.58972 1.30661 1.57136 1.57136
Diluted EPS Excluding Extraordinary Items -72.1171 -44.5123 -25.0363 -13.2077
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -54.8939 -45.932 -25.0281 -13.1186
Unusual Expense (Income) 20.473 -1.827
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0.107 0.008 0.138 0.361
Revenue 0 0.107 0.008 0.138 0.361
Total Operating Expense 9.129 67.256 27.76 40.77 22.99
Selling/General/Admin. Expenses, Total 8.877 9.617 10.936 9.584 8.164
Research & Development 0.203 6.996 16.581 11.859 13.923
Operating Income -9.129 -67.149 -27.752 -40.632 -22.629
Interest Income (Expense), Net Non-Operating 0.42 0.425 0.259 0.045 -0.065
Other, Net 1.005 1.053 0.486 0.216 0
Net Income Before Taxes -6.95 -65.808 -27.008 -40.371 -22.7
Net Income After Taxes -6.95 -62.347 -27.008 -40.371 -22.7
Net Income Before Extra. Items -6.95 -62.347 -27.008 -40.371 -22.7
Net Income -6.95 -62.347 -27.008 -40.371 -22.7
Income Available to Common Excl. Extra. Items -6.95 -62.347 -27.008 -40.371 -22.7
Income Available to Common Incl. Extra. Items -6.95 -62.347 -27.008 -40.371 -22.7
Diluted Net Income -6.95 -62.347 -27.008 -40.371 -22.7
Diluted Weighted Average Shares 1.6048 1.6043 1.5977 1.59078 1.58572
Diluted EPS Excluding Extraordinary Items -4.33077 -38.8624 -16.9043 -25.3781 -14.3153
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -4.77008 -18.2883 -16.7516 -13.2287 -13.742
Unusual Expense (Income) 0.049 50.643 0.243 19.327 0.903
Gain (Loss) on Sale of Assets 0.754 -0.137 -0.001 0 -0.006
Other Operating Expenses, Total 0
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 74.551 142.551 106.164 48.626
Cash and Short Term Investments 71.038 133.481 99.71 42.186
Cash & Equivalents 71.038 133.481 99.71 42.186
Total Receivables, Net 0.144 0.494 1.095 4.746
Accounts Receivable - Trade, Net 0.144 0.494 1.034 1.178
Prepaid Expenses 3.369 8.576 5.359 1.694
Total Assets 162.939 225.369 165.338 103.569
Property/Plant/Equipment, Total - Net 48.688 24.688 7.004 3.776
Property/Plant/Equipment, Total - Gross 57.974 28.914 9.033 5.034
Accumulated Depreciation, Total -9.286 -4.226 -2.029 -1.258
Goodwill, Net 0 18.057 18.057 18.057
Intangibles, Net 32.9 32.9 32.9 32.9
Other Long Term Assets, Total 6.8 7.173 1.213 0.21
Total Current Liabilities 14.689 14.79 11.486 7.325
Accounts Payable 1.097 3.737 2.621 0.655
Accrued Expenses 13.592 11.053 5.228 3.958
Notes Payable/Short Term Debt 0 0 0 0
Other Current Liabilities, Total 0 3.637 2.712
Total Liabilities 67.228 23.145 28.002 19.954
Total Long Term Debt 14.653 0.007 1.808 0
Long Term Debt 14.653 0 1.808 0
Deferred Income Tax 3.461 3.461 3.461 3.461
Other Liabilities, Total 34.425 4.887 11.247 9.168
Total Equity 95.711 202.224 137.336 83.615
Redeemable Preferred Stock 233.054 143.15
Common Stock 0.048 0.047 0.008 0.008
Additional Paid-In Capital 371.304 363.172 7.109 3.951
Retained Earnings (Accumulated Deficit) -275.641 -160.995 -102.835 -63.494
Total Liabilities & Shareholders’ Equity 162.939 225.369 165.338 103.569
Total Common Shares Outstanding 1.60163 1.58358 1.57136 1.57136
Capital Lease Obligations 0 0.007
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 29.919 36.499 43.397 74.551 90.616
Cash and Short Term Investments 28.779 34.051 41.684 71.038 85.292
Cash & Equivalents 28.779 34.051 41.684 71.038 85.292
Total Receivables, Net 0 0 0.107 0.144 0
Accounts Receivable - Trade, Net 0 0 0.107 0.144 0
Prepaid Expenses 1.14 2.448 1.606 3.369 5.324
Total Assets 59.493 66.857 79.04 162.939 187.968
Property/Plant/Equipment, Total - Net 27.226 28.04 33.075 48.688 57.635
Property/Plant/Equipment, Total - Gross 27.458 28.286 35.351 57.974 65.956
Accumulated Depreciation, Total -0.232 -0.246 -2.276 -9.286 -8.321
Goodwill, Net 0 0
Intangibles, Net 0 0 0 32.9 32.9
Other Long Term Assets, Total 2.348 2.318 2.568 6.8 6.817
Total Current Liabilities 4.879 9.575 13.206 14.689 13.808
Accounts Payable 0.357 0.432 2.553 1.097 1.06
Accrued Expenses 4.522 9.143 10.653 13.592 12.748
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total
Total Liabilities 33.68 38.963 46.088 67.228 67.102
Total Long Term Debt 0 0 0 14.653 14.636
Long Term Debt 0 0 0 14.653 14.636
Deferred Income Tax 0 0 0 3.461 3.461
Other Liabilities, Total 28.801 29.388 32.882 34.425 35.197
Total Equity 25.813 27.894 32.952 95.711 120.866
Redeemable Preferred Stock
Common Stock 0.002 0.002 0.048 0.048 0.048
Additional Paid-In Capital 373.165 372.83 372.484 371.304 369.451
Retained Earnings (Accumulated Deficit) -347.354 -344.938 -339.58 -275.641 -248.633
Total Liabilities & Shareholders’ Equity 59.493 66.857 79.04 162.939 187.968
Total Common Shares Outstanding 1.60503 1.60476 1.60467 1.60163 1.59406
Capital Lease Obligations 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -114.646 -58.16 -39.341 -20.754
Cash From Operating Activities -74.851 -67.133 -31.329 -17.32
Cash From Operating Activities 5.507 2.301 0.79 0.482
Non-Cash Items 35.852 3.238 3.112 0.746
Cash Interest Paid 0.741 0.009 0.011 0.008
Changes in Working Capital -1.564 -14.512 4.11 2.206
Cash From Investing Activities -2.182 -15.921 -2.633 -0.973
Capital Expenditures -2.182 -15.983 -2.633 -1.005
Other Investing Cash Flow Items, Total 0 0.062 0 0.032
Cash From Financing Activities 14.873 119.11 91.475 53.3
Financing Cash Flow Items -0.132 0.39 -0.249 0
Issuance (Retirement) of Stock, Net 0.289 118.747 89.963 48.571
Issuance (Retirement) of Debt, Net 14.716 -0.027 1.761 4.729
Net Change in Cash -62.16 36.056 57.513 35.007
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -63.939 -114.646 -87.638 -47.267 -24.567
Cash From Operating Activities -13.381 -74.851 -60.579 -41.485 -25.646
Cash From Operating Activities 1.367 5.507 4.099 2.694 1.331
Non-Cash Items 49.749 35.852 26.117 4.959 2.362
Cash Interest Paid 0.202 0.741 0.407 0.073 0.002
Changes in Working Capital 2.903 -1.564 -3.157 -1.871 -4.772
Cash From Investing Activities -0.014 -2.182 -2.131 -1.803 -0.909
Capital Expenditures -0.014 -2.182 -2.131 -1.803 -0.909
Other Investing Cash Flow Items, Total 0 0 0 0
Cash From Financing Activities -16.159 14.873 14.821 14.78 0.005
Financing Cash Flow Items -1.155 -0.132 -0.132 -0.132 0
Issuance (Retirement) of Stock, Net 0 0.289 0.229 0.185 0.014
Issuance (Retirement) of Debt, Net -15.004 14.716 14.724 14.727 -0.009
Net Change in Cash -29.554 -62.16 -47.889 -28.508 -26.55
Deferred Taxes -3.461
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Crestovo Investor LLC Corporation 26.2582 421381 0 2023-04-10 LOW
Haft (Nicholas) Individual Investor 8.4268 135230 0 2023-04-10 LOW
Ugwumba (Chidozie) Individual Investor 7.2701 116667 0 2023-04-10 LOW
The Baupost Group, L.L.C. Investment Advisor/Hedge Fund 4.1935 67296 -4 2023-06-30
Smith (Mark Burnham) Individual Investor 3.9529 63434 0 2023-04-10 LOW
Susquehanna International Group, LLP Investment Advisor 3.6783 59028 -1 2023-06-30 MED
Smisek (Jeffery A) Individual Investor 3.5198 56485 0 2023-04-10 LOW
Avenir Management Co, LLC Investment Advisor 3.455 55445 -1 2023-06-30 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.0362 32676 -1157 2023-06-30 LOW
FERRANTE DOMENIC J Individual Investor 1.3215 21207 0 2023-04-10 LOW
Lake Street Advisors Investment Advisor 1.3214 21206 -3432 2023-06-30 LOW
Ikarian Capital LLC Hedge Fund 0.4933 7917 -1 2023-06-30 HIGH
Greenwich Ivy Capital LLC Hedge Fund 0.4672 7497 0 2023-06-30 HIGH
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.2967 4761 0 2023-09-30 LOW
Vittiglio Joseph D Individual Investor 0.0651 1045 -1 2023-04-10 MED
Bleichroeder LP Investment Advisor 0.0605 971 -26043 2023-06-30 LOW
Blaustein (Marc) Individual Investor 0.0581 933 41 2023-04-10 LOW
Tower Research Capital LLC Hedge Fund 0.0409 657 360 2023-06-30 HIGH
UBS Financial Services, Inc. Investment Advisor 0.0338 543 541 2023-06-30 LOW
Ancora Advisors, L.L.C. Investment Advisor/Hedge Fund 0.0332 533 0 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Finch Therapeutics Group, Inc. Company profile

About Finch Therapeutics Group Inc

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. The Company leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. It is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). It is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Finch Therapeutics Group Inc revenues increased from $5.9M to $17.7M. Net loss increased 49% to $39.1M. Revenues reflect Collaboration revenue increase from $5.6M to $17.7M. Higher net loss reflects Research and development - Balancing val increase of 69% to $41.3M (expense), General and administrative - Balancing increase of 93% to $14.6M (expense).

Industry: Biotechnology & Medical Research (NEC)

75 State Street
Suite 100
BOSTON
MASSACHUSETTS 02109
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

Oil - Crude

76.11 Price
-0.570% 1D Chg, %
Long position overnight fee 0.0165%
Short position overnight fee -0.0384%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.54 Price
-1.220% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

51,587.90 Price
-0.060% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,032.62 Price
-0.170% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 22:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading